Product Pipeline / ATROSIMAB
The monovalent TNF-R1 antagonist
Lead compound for the treatment of chronic liver diseases.
Atrosimab is Baliopharm´s follow on product of the full-length antibody Atrosab and likewise specifically targets the pro-inflammatory TNF receptor 1 (TNF-R1). Atrosimab has been affinity matured and is expressed as a monovalent antibody format lacking the hinge region and the CH1 domain. The optimization process resulted in several favorable characteristics compared to Atrosab including a 3,6-fold stronger inhibition of TNF-R1 activation, a 5-fold more effective inhibition of TNF-alpha induced cell death and a 6-fold more potent inhibition of TNF-alpha mediated release of the pro-inflammatory cytokines IL-6 and IL-8. Additionally, Atrosimab has been designed to feature a longer half-life than standard Fab and scFv fragments.
Atrosimab has successfully completed a phase I clinical trial in healthy volunteers with proven safety and tolerability.